Gilead Sciences (NASDAQ:GILD) Price Target Raised to $175.00

Key Points

• Morgan Stanley raised its price target to $175 (from $171) and kept an "overweight" rating, implying about a 24.7% upside; multiple other analysts have also lifted targets, leaving the MarketBeat consensus target at $156.42 with 24 Buys and 4 Holds.
• Gilead beat quarterly estimates with $1.86 EPS and $7.93B revenue, set FY2026 guidance of 8.45–8.85 EPS, and the stock was trading around $140.37 with a market cap of about $174.2B and a P/E of 20.77.
• Management is pursuing an oncology push—announcing a potential $5 billion acquisition of Tubulis and licensing deals (including a $45M trigger for Kymera’s KT‑200)—while insiders have sold roughly 299,280 shares (~$42.8M) over the past three months.

Gilead Sciences (NASDAQ:GILD - Get Free Report) had its price target lifted by stock analysts at Morgan Stanley from $171.00 to $175.00 in a report issued on Friday,Benzinga reports. The firm presently has an "overweight" rating on the biopharmaceutical company's stock. Morgan Stanley's price target would indicate a potential upside of 24.67% from the company's current price.

Other research analysts also recently issued reports about the company. Rothschild & Co Redburn raised their price target on Gilead Sciences from $159.00 to $170.00 and gave the company a "buy" rating in a research note on Tuesday, February 17th. Wolfe Research boosted their price objective on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an "outperform" rating in a research note on Thursday, February 12th. Argus boosted their price objective on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a "buy" rating in a research note on Thursday, February 19th. Wells Fargo & Company boosted their price objective on shares of Gilead Sciences from $150.00 to $165.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 11th. Finally, BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an "outperform" rating in a research note on Monday, January 26th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $156.42.

Gilead Sciences Stock Down 1.2%

GILD traded down $1.72 during trading hours on Friday, hitting $140.37. 716,835 shares of the company's stock were exchanged, compared to its average volume of 6,988,719. Gilead Sciences has a 1-year low of $93.37 and a 1-year high of $157.29. The stock's 50-day moving average is $145.19 and its two-hundred day moving average is $130.18. The stock has a market cap of $174.23 billion, a price-to-earnings ratio of 20.77, a PEG ratio of 1.88 and a beta of 0.39. The company has a quick ratio of 1.40, a current ratio of 1.55 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, beating analysts' consensus estimates of $1.83 by $0.03. The firm had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business's revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts predict that Gilead Sciences will post 7.95 earnings per share for the current fiscal year.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $144.23, for a total transaction of $432,690.00. Following the completion of the sale, the chief financial officer directly owned 179,191 shares in the company, valued at $25,844,717.93. This trade represents a 1.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the completion of the transaction, the chief executive officer owned 642,308 shares in the company, valued at $92,999,775.32. This trade represents a 1.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 299,280 shares of company stock valued at $42,820,550. 0.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds and other institutional investors have recently made changes to their positions in GILD. Norges Bank acquired a new position in Gilead Sciences in the 4th quarter valued at $2,617,152,000. Ameriprise Financial Inc. boosted its stake in Gilead Sciences by 397.6% in the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company's stock valued at $748,147,000 after buying an additional 5,392,191 shares in the last quarter. Boston Partners acquired a new stake in Gilead Sciences in the fourth quarter valued at about $517,808,000. Massachusetts Financial Services Co. MA grew its stake in shares of Gilead Sciences by 3,763.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company's stock worth $518,368,000 after buying an additional 4,113,999 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Gilead Sciences by 15.2% during the fourth quarter. Bank of America Corp DE now owns 23,121,620 shares of the biopharmaceutical company's stock worth $2,837,948,000 after buying an additional 3,046,688 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Announced acquisition of Tubulis for up to $5 billion to bolster Gilead’s antibody–drug conjugate (ADC) oncology capabilities — strengthens pipeline and R&D capacity. Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline
• Positive Sentiment: Gilead exercised an option to license Kymera’s KT‑200 (oral CDK2 molecular glue degrader), triggering a $45M milestone payment — expands small‑molecule degrader capabilities and pipeline diversity. Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200
• Positive Sentiment: Gilead exercised an option stemming from its Cartography collaboration to license a novel oncology target, further validating external discovery partnerships. Cartography Biosciences Advances Strategic Oncology Collaboration with Gilead’s First Option Target Exercise
• Positive Sentiment: Expanded multi‑year collaboration with Tempus to use real‑world evidence and AI in oncology R&D — supports clinical development and patient selection for Gilead’s cancer programs. Tempus Announces Strategic Collaboration with Gilead to Advance Oncology R&D Through RWE
• Positive Sentiment: Truist raised its price target on GILD to $155 (from $152) and reiterated a Buy, citing easing sector headwinds and pickup in deal activity. Gilead price target raised to $155 from $152 at Truist
• Neutral Sentiment: Market commentary notes Gilead’s recent string of buyouts (including Tubulis) signals a strategic shift toward oncology/autoimmune; integration and execution will determine long‑term value. With 3 quick buyouts, Gilead leans into its latest transformation
• Neutral Sentiment: Analyst and media pieces highlight Gilead’s strong earnings‑surprise history and favorable fundamentals, but note the company still must execute on pipeline integration. Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.